PDCD1 and cancer: In 2021, Galecto Biotech announced entering an agreement with Roche for a Phase IIa trial of GB1211 in combination with a PD-1/-L1 checkpoint inhibitor atezolizumab for the treatment of cancer (Tecentriq, start in 2022, GALLANT-1: NCT05240131).290